Novonesis A/S

CPSE:NSIS B Voorraadrapport

Marktkapitalisatie: DKK 192.5b

Novonesis Toekomstige groei

Future criteriumcontroles 3/6

Novonesis zal naar verwachting groeien in winst en omzet met respectievelijk 30.7% en 10.1% per jaar. De winst per aandeel zal naar verwachting groeien met 21.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 8.1% zijn.

Belangrijke informatie

30.7%

Groei van de winst

21.7%

Groei van de winst per aandeel

Chemicals winstgroei21.8%
Inkomstengroei10.1%
Toekomstig rendement op eigen vermogen8.1%
Dekking van analisten

Good

Laatst bijgewerkt23 Nov 2024

Recente toekomstige groei-updates

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05
An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Jul 09
Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Jun 24
Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

May 02
Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Apr 07
Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Mar 26
Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Mar 12
Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Feb 04
Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jan 29
Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Dec 23
Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Dec 05
Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Oct 14
A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29
The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13
Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13
Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29
Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

Winst- en omzetgroeiprognoses

CPSE:NSIS B - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20264,5298278741,33213
12/31/20254,2307017811,23914
12/31/20243,9463126271,03614
6/30/20243,045283598891N/A
3/31/20242,696332486779N/A
12/31/20232,401406281557N/A
9/30/20232,390430169485N/A
6/30/20232,38246083436N/A
3/31/20232,39048783476N/A
12/31/20222,360494150539N/A
9/30/20222,268460206554N/A
6/30/20222,186418262539N/A
3/31/20222,090416337530N/A
12/31/20212,009423379546N/A
9/30/20211,958427461593N/A
6/30/20211,914409432564N/A
3/31/20211,883389443577N/A
12/31/20201,883380459585N/A
9/30/20201,920415442521N/A
6/30/20201,955405465536N/A
3/31/20201,968439407482N/A
12/31/20191,924422352428N/A
9/30/20191,923411316460N/A
6/30/20191,917434350505N/A
3/31/20191,922417309477N/A
12/31/20181,927432306493N/A
9/30/20181,924427303515N/A
6/30/20181,915429262490N/A
3/31/20181,920423N/A501N/A
12/31/20171,952419N/A546N/A
9/30/20171,958421N/A533N/A
6/30/20171,934412N/A522N/A
3/31/20171,919414N/A547N/A
12/31/20161,902410N/A517N/A
9/30/20161,864394N/A488N/A
6/30/20161,883394N/A437N/A
3/31/20161,883384N/A450N/A
12/31/20151,876378N/A447N/A
9/30/20151,840366N/A395N/A
6/30/20151,795353N/A443N/A
3/31/20151,741340N/A454N/A
12/31/20141,673339N/A608N/A
9/30/20141,641334N/A680N/A
6/30/20141,605324N/A643N/A
3/31/20141,598319N/A567N/A
12/31/20131,575295N/A348N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei NSIS B ( 30.7% per jaar) ligt boven de spaarquote ( 1.2% ).

Winst versus markt: De winst van NSIS B ( 30.7% per jaar) zal naar verwachting sneller groeien dan de Danish markt ( 11.9% per jaar).

Hoge groeiwinsten: De winst van NSIS B zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van NSIS B ( 10.1% per jaar) zal naar verwachting langzamer groeien dan de markt Danish ( 10.1% per jaar).

Hoge groei-inkomsten: De omzet van NSIS B ( 10.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen NSIS B zal naar verwachting over 3 jaar laag zijn ( 8.1 %).


Ontdek groeibedrijven